Sandoz Says High Court Should Review BPCIA To Avoid Delay For Patient Access To Biosimilar

Mealey's (July 15, 2016, 10:01 AM EDT) -- WASHINGTON, D.C. — Sandoz Inc. argues in a brief filed May 31 that the U.S. Supreme Court should consider reviewing the Biologics Price Competition and Innovation Act (BPCIA) because until it does the Federal Circuit U.S. Court of Appeals’ decision will delay patient access to every biosimilar for at least six months after the biosimilar has been approved by the Food and Drug Administration (Sandoz, Inc. v. Amgen, Inc. and Amgen Manufacturing, Ltd., No. 15-1039, U.S. Sup.; Amgen Inc. et al. v. Sandoz Inc., No. 15-1195,...
To view the full article, register now.